Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash

Aquestive Therapeutics disclosed an investor presentation detailing an NDA resubmission for Anaphylm and its cash runway of $98.5 million.Key Highlights:Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K - Sep. 25, 2026This is an AI-powered summary. It may contain inaccuracies. Consid…